The elections will take place from 23 May - 5 June 2022 and is held online via the link https://icnapedia.org/ballot-2022 . All eligible voters will be sent their unique codes during the perior 23 May 2022 - 25 May 2022 . The codes are sent out in batches. Please only contact us if you have not received your unique voting code by 26 MAY 2020. Meanwhile we would strongly encourage you to go through the candidate statements , which are now available online. Any new ICNA members, including those who have been converted to FULL Membership from JUNIOR Membership after 23 May 2020 will NOT be eligible to vote in this election. The election site will be open tilll 5 June 2022 6PM CET.
• To learn current diagnostic criteria for NMO/NMOSD.
• To know updated information on the diagnostic biomarkers and appropriate laboratory techniques.
• To learn current rescue therapies for acute events, and introducing novel relapse prevention strategies for patients with NMOSD.
- Learn new clinical and neuroimaging diagnostic criteria for NMO/NMOSD and corresponding biomarkers.
- Receive updated information on current rescue therapies for severe acute CNS events, and learn on relapse prevention strategies, including novel immunosuppressive drugs.
- Make appropriate diagnosis of NMOSD.
- Recognize relevant data about treatment options that should be considered for the correct treatment of acute events and relapse prevention with immunosuppression in children.
Silvia N. Tenembaum, MD; National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina
Introduction: Current Diagnostic Criteria of Neuromyelitis Optica Spectrum Disorders (NMOSD)
Silvia N. Tenembaum, MD
Dr. Juan P. Garrahan
Diagnostic Biomarkers of NMOSD: AQP4-IgG and MOG-IgG
Thaís Armangue, MD, PhD; IDIBAPS-Hospital Clinic, University of Barcelona, Sant Joan de Déu Children’s Hospital, University of Barcelona, Barcelona, Spain
Treatment of Acute Clinical Events
Andrea Savransky, MD; National Pediatric Hospital Dr. J. P. Garrahan, Buenos Aires, Argentina Wednesday, October 21 24 ICNA • CNS | San Diego 2020
Current Preventive Treatment Strategies for NMOSD
E. Ann Yeh, MD, MA, FRCPC; Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
New Era on Preventive Treatment of NMOSD: Recently Approved and Investigational Agents
Tanuja Chitnis, MD, FAAN; Harvard Medical School, Boston, Massachusetts, USA